AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.9 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Ribosome biogenesis: A central player in liver diseases

Wei Luoa,b,1Jing Zhoua,bYongmin Yana,b,c( )Xuezhong Xua,b( )
Changzhou Key Laboratory of Molecular Diagnostics and Precision Cancer Medicine, Wujin Hospital Affiliated with Jiangsu University (Wujin Clinical College of Xuzhou Medical University), Changzhou, Jiangsu 213017, China
Wujin Institute of Molecular Diagnostics and Precision Cancer Medicine of Jiangsu University, Changzhou, Jiangsu 213017, China
Department of Laboratory Medicine, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu 213017, China

Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA).

1 These authors contributed equally to this work.

Show Author Information

Abstract

Ribosome biogenesis is a multi-step process that initiates within the nucleolus, terminates in the cytoplasm, and determines the rate of protein synthesis. Ribosome biogenesis is essential for maintaining liver function. In eukaryotes, it involves producing and assembling approximately 200 factors and 80 ribosomal proteins. Mutations in ribosome proteins, ribosomal RNA processing, and ribosome assembly factors in the liver can result in liver disease. Hepatitis C virus causes acute or chronic infection and liver disease, which can progress to liver cirrhosis, cancer, and death. This review provides an overview of the effects of ribosomal biogenesis, including ribosomal RNA, ribosomal proteins, and ribosome biogenesis factors, on liver regeneration, hepatitis C virus, nonalcoholic fatty liver disease, liver fibrosis, cirrhosis, and liver cancer. It lists drugs that exploit ribosome biogenesis to treat liver cancer. Targeting ribosome biogenesis shows promise as a therapeutic approach. A better understanding of this process will contribute to developing effective and targeted therapeutic strategies for ribosome biogenesis disorders.

References

【1】
【1】
 
 
Genes & Diseases
Article number: 101512

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Luo W, Zhou J, Yan Y, et al. Ribosome biogenesis: A central player in liver diseases. Genes & Diseases, 2025, 12(5): 101512. https://doi.org/10.1016/j.gendis.2025.101512

704

Views

1

Downloads

3

Crossref

5

Web of Science

5

Scopus

0

CSCD

Received: 13 June 2024
Accepted: 02 December 2024
Published: 04 January 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).